These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25634708)

  • 1. Managing attention-deficit/hyperactivity disorder in children and adolescents.
    McClain EK; Burks EJ
    Prim Care; 2015 Mar; 42(1):99-112. PubMed ID: 25634708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder.
    Handen BL; Taylor J; Tumuluru R
    Int J Adolesc Med Health; 2011; 23(3):167-73. PubMed ID: 22191179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis and medical treatment of ADHD in children and adolescents in primary care: a practical guide.
    Woodard R
    Pediatr Nurs; 2006; 32(4):363-70. PubMed ID: 16927730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs for treatment of ADHD.
    Treat Guidel Med Lett; 2011 May; 9(105):23-8; quiz 2 p following 28. PubMed ID: 21519317
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informed consent and stimulant medication: adolescents' and parents' ability to understand information about benefits and risks of stimulant medication for the treatment of attention-deficit/hyperactivity disorder.
    Schachter D; Tharmalingam S; Kleinman I
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):139-48. PubMed ID: 21504355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder.
    Brinkman WB; Sherman SN; Zmitrovich AR; Visscher MO; Crosby LE; Phelan KJ; Donovan EF
    Pediatrics; 2009 Aug; 124(2):580-9. PubMed ID: 19651580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.
    McCabe SE; Dickinson K; West BT; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):479-86. PubMed ID: 27238066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.